Coherus shares fell 21.6% after earnings, as investors appear to have focused on the company’s need to sharply reduce costs and its reliance on growing LOQTORZI revenue to cover core cash burn. Management plans a 30% headcount reduction and narrowed tagmokitug development to esophageal cancer, but the transcript does not provide evidence that LOQTORZI has yet reached the revenue level needed to support the business.
- Coherus expects rightsizing and other cost reductions to save $6 million–$7 million per quarter, lowering the LOQTORZI revenue needed to cover core cash burn from $30 million–$35 million to $25 million–$30 million per quarter.
- The company plans to cut headcount by 30% and focus tagmokitug development on first- and second-line esophageal cancer, after exploring multiple cancer types and more than 120 patients.
- Management cited interim tagmokitug data in combination with toripalimab as support for seeking ex-U.S. partners; it is engaging a financial adviser to conduct the partnering process.
- LOQTORZI’s share of the nasopharyngeal cancer market is about 20%–22%, while roughly 30% of patients still receive chemotherapy alone, which management sees as a growth opportunity.
- Management said the U.S. manufacturing process transfer for toripalimab was completed in Q3 2026; the FDA action date for the drug-product portion of the application is November 30.
Community Discussion